FCGR1A and neoplasm: As expected, we observed longer OS in tislelizumab-treated patients with a higher density of CD64+ Mφ and found that CD64 + Mφ density was positively associated with enrichment of immune-activating pathways (e.g., IFNγ response, cytotoxic cell, and antigen presentation), and negative association with pro-tumor signals (e.g., TGFβ, Wnt signaling, and tumor proliferation).